Trial Profile

The Efficacy and Adverse Effects of Olaparib in Ovarian Cancer: a Prospective Real-world Product Registration Study.

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 19 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary)
Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

12 Jun 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Jan 2024.
23 Feb 2021 Status changed from not yet recruiting to recruiting.
08 Jan 2021 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com